NCT02955082 2026-02-04
BARCODE2
Institute of Cancer Research, United Kingdom
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT01741116 2021-02-18
Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer
Korean Cancer Study Group
Phase 2 Completed
NCT02867345 2019-03-06
PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer
Peking University
Withdrawn
NCT00928252 2017-08-14
Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer
Queen's Medical Center
Phase 1/2 Completed
NCT01518283 2017-07-02
Study of Weekly Cabazitaxel for Advanced Prostate Cancer
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT00629525 2015-03-03
RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer
Duke University
Phase 2 Completed
NCT02208583 2014-08-05
Molecular Phenotype Changes and Personalized Treatment for CRPC
Tianjin Medical University Cancer Institute and Hospital
Phase NA Unknown
NCT00313482 2012-05-11
PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC
Veeda Oncology
Phase 2 Terminated
NCT00906243 2012-04-04
RNActive®-Derived Therapeutic Vaccine
University of Florida
Phase 1/2 Terminated
NCT00407251 2010-11-05
Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy
British Columbia Cancer Agency
Phase 2 Completed
NCT00795171 2010-08-18
Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer
Medical University of Vienna
Phase 2 Unknown